Healthcare Services

Oncology Based In-Vivo CRO Market 2026–2030: Forecasting Business Opportunities Ahead

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oncology based in-vivo cro market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Oncology Based In-Vivo CRO Market between 2026 and 2030?

The oncology based in-vivo cro market has experienced rapid expansion in recent years. This market is anticipated to grow from $1.5 billion in 2025 to $1.66 billion in 2026, at a compound annual growth rate (CAGR) of 10.6%. Several key factors contributed to its historical growth, including the increasing demand for preclinical oncology studies, the rise of animal model-based research, the growing prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. This growth during the forecast period can be attributed to an increasing focus on patient-derived xenograft models, enhanced integration of digital data management systems, the progression of personalized oncology drug development, a rise in the outsourcing of in-vivo studies to specialized CROs, and the broader adoption of automated imaging and monitoring solutions. Prominent trends expected in the forecast period include the increasing uptake of digital platforms for in-vivo study management, a greater utilization of AI and machine learning in preclinical oncology research, the expanding implementation of genomic profiling for patient-derived xenograft models, rising automation in in-vivo testing and data analysis, and the growing use of IoT-enabled monitoring for laboratory equipment and study outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Drivers Are Expected To Impact The Oncology Based In-Vivo CRO Market During The Forecast Period?

The rising incidence of cancer is anticipated to stimulate the expansion of the oncology-based in-vivo CRO market moving forward. Cancer describes a collection of diseases where abnormal cells multiply uncontrollably, extend beyond their typical boundaries, can originate in nearly any organ or tissue, and spread through the blood and lymph systems to other body parts. The effective treatment and diagnosis of cancer necessitate innovative drugs and devices, which undergo various preclinical trials, clinical trials, and regulatory processes prior to their market introduction. An oncology in-vivo-based CRO is a firm engaged by a sponsoring company to deliver research services, such as performing all or part of a preclinical in-vivo study (testing involving living organisms like animals, plants, or whole cells) before a drug or device proceeds to human trials. With the increasing prevalence of cancer, the demand for novel treatments and therapies has also escalated, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. An estimated 620,000 cancer deaths are projected for 2024, representing a slight increase in mortality rates. This growing prevalence of cancer is driving the oncology-based in-vitro CRO market.

How Is The Oncology Based In-Vivo CRO Market Divided Into Segments?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

What Long-Term Trends Are Expected To Shape The Future Of The Oncology Based In-Vivo CRO Market?

Major companies operating within the oncology-based in vivo CRO market are strategically focusing on introducing novel solutions, such as CAR T-cell therapies, to gain a significant competitive edge. CAR T-cell therapy functions as a type of immunotherapy, employing T cells that have been specifically altered to target and eliminate cancer cells. For example, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, launched BrainChild Bio, an initiative designed to accelerate CAR T-cell therapies for children diagnosed with brain tumors. The initial pediatric brain tumors that BrainChild Bio plans to address with CAR T-cell therapy are diffuse intrinsic pontine gliomas (DIPG), an incurable childhood condition that develops in the brainstem. BrainChild Bio represents a next-generation CAR T-cell treatment platform, incorporating advanced synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After securing pediatric registration for DIPG, BrainChild Bio intends to apply its innovative CAR T-cell therapy to treat a wider range of challenging-to-cure adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Major Firms Are Strengthening Their Position In The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncology Based In-Vivo CRO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Oncology Ablation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-ablation-global-market-report

Oncology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795